TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05097248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
Study: NCT06517862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
Study: NCT05066633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be in the form of identical tablets and will be administered orally once daily.
Study: NCT05457348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planned incisions during phacoemulsification
Description: Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Planned incisions during phacoemulsification
Description: Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
Study: NCT05043623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined nose and throat swab
Description: Combined nose and throat swab (standard of care)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined nose and throat swab
Description: Combined nose and throat swab (standard of care)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva swab
Description: Saliva swab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva swab
Description: Saliva swab

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbott Panbio™ COVID-19 antigen self-test kit
Description: COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
Study: NCT05900921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion, d1
Study: NCT06091358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrO2
Description: The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week.~Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day each week.
Study: NCT05900921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion, d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: IV infusion, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: IV infusion, d1
Study: NCT05035446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-incision plus one-port laparoscopic surgery
Description: The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional laparoscopic surgery
Description: It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
Study: NCT05736094

Intervention type: DEVICE
Group type: OTHER
Intervention: SURF
Description: Dual-frequency ultrasound
Study: NCT04724330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy for Two/Healthy for You
Description: \~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
Study: NCT05455580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurses Taking On Readiness Measures (N-TORM)
Description: The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
Study: NCT05783752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair Stepping
Description: 1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair Stepping
Description: 1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise control
Description: Participants avoid exercise within 1 hour of eating a meal

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise control
Description: Participants avoid exercise within 1 hour of eating a meal
Study: NCT05465954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT05644002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Puff Topography Biofeedback Training
Description: Visit 1: Participants will be asked to smoke their usual brand cigarette using the CReSS smoking topography device. Participants will be instructed on how to follow visual and auditory puffing prompts provided to them by a computer program in order to control puffing behavior for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Visit 1: Participants will be instructed to smoke their usual brand cigarette using the CReSS smoking topography device while passively viewing time-matched control stimulus presented to them on a computer monitor for a duration of five minutes.~Visit 2: Participants will be instructed to smoke their cigarette using the CReSS device and instructions provided during Visit 1 after undergoing a brief laboratory stress induction.
Study: NCT05807568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCAEM EM-SART Pre-Screen
Description: Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
Study: NCT05195489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Connectors
Description: The Family Connectors Program is a manualized program that uses a time-limited parent-to parent (i.e. peer parent) support and education program delivered by phone to families of youth with serious mental health difficulties, assisting family members in becoming fully engaged with provider teams who coordinate and provide care. Family Connectors is delivered weekly by phone over the course of between three and six months.
Study: NCT05991128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: n the placebo group, patients will receive the equivalent number of normal saline injections.
Study: NCT06453239

Intervention type: DIAGNOSTIC_TEST
Intervention: Pro-Neurotensin level as a Serum Biomarker
Description: Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pro-Neurotensin level as a Serum Biomarker
Description: Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
Study: NCT05828732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using a mobile app that integrates with wearable devices
Description: Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
Study: NCT05682313

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elastography arm
Description: Renal ultrasound elastography to detect and classify the degree of fibrosis
Study: NCT06225115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYN-5356
Description: KYN-5356, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo, oral tablet
Study: NCT05689593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity ESWT Group
Description: ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity laser Group
Description: The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Control Group
Description: Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Control Group
Description: Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Control Group
Description: Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
Study: NCT04310358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 short PLMs group 1
Description: Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
Study: NCT05341570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-21668
Description: Subjects will receive BPI-21668 until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-21668
Description: Subjects will receive BPI-21668 until disease progression
Study: NCT05889351

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel, 4 + 4 applications or 4 + 2 applications
Description: Control arm/placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109 3% gel, 4 + 4 applications
Description: Cohort 1 active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTX-109 3% gel, 4 + 2 applications
Description: Cohort 2 active treatment
Study: NCT04310358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 short PLMs group 2
Description: Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
Study: NCT05646329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
Study: NCT05987917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-2
Description: Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-2
Description: Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Treatment
Description: The subject who will serve as control will not be treated with the study device.
Study: NCT06515301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.
Description: Information already available

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.
Description: Information already available

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.
Description: Information already available

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.
Description: Information already available
Study: NCT04782193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted prime CAR- T cells
Description: A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
Study: NCT05107349

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Description: A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
Study: NCT06676943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XEOS AURA 10 specimen PET-CT scan of tumour specimens
Description: Participants will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen and assess the margin.
Study: NCT06382649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Study: NCT05474911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional wound care
Description: The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.